• FDA Approves Potentially Life Saving GVOKE: Xeris’ Ready-to-Use Glucagon

    By Jimmy McDermott

    A new premixed, liquid glucagon coming in October in a prefilled syringe and in 2020 as an auto-injector. The second stable glucagon approved this year

    The FDA has approved GVOKE, a glucagon injection for the treatment of dangerously low blood sugar (severe hypoglycemia) in people with diabetes who are at least two years of age. Xeris Pharmaceutical’s GVOKE is room-temperature, liquid, stable glucagon that is ready-to-use in an emergency. It will first be launched in the US in a prefilled syringe, coming to pharmacies in October 2019. An EpiPen-like auto-injector, GVOKE HypoPen, will be launched at some point in 2020.

    Gvoke 2 Gvoke 2